Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab

Defining how epidermal growth factor receptor (EGFR)-targeting therapies influence the immune response is essential to increase their clinical efficacy. A growing emphasis is being placed on immune regulator genes that govern tumor – T cell interactions. Previous studies showed an increase in HLA cl...

Full description

Bibliographic Details
Main Authors: Greta Garrido, Ailem Rabasa, Cristina Garrido, Lisset Chao, Federico Garrido, Ángel M. García-Lora, Belinda Sánchez-Ramírez
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-10-01
Series:Frontiers in Pharmacology
Subjects:
nimotuzumab
EGFR
HLA class I molecules
antibodies
tumor cells
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00595/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00595/full

Similar Items